Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus monotherapy conversion for calcineurin inhibitor complications in liver transplant recipients
2007-007907-34Phase 2Active
- Sponsor
- AOU Policlinico di Modena
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in Orthotopic liver transplantation (OLT), calcineurin inhibitor neurotoxicity (CIN), calcineurin inhibitor nephrotoxicity and 2 more, sponsored by AOU Policlinico di Modena. Primary endpoints: Feasibility and safety of Sirolimus monotherapy, Improvement in renal function and 3 more. Started Jan 2008; status: active.
02
Drugs
sirolimus
03
Conditions
Orthotopic liver transplantation (OLT)calcineurin inhibitor neurotoxicity (CIN)calcineurin inhibitor nephrotoxicityCalcineurin inhibitor-related metabolic complications (CNI-MC)calcineurin inhibitor-induced cardiovascular complications (CNI-CVC)
Beyond the preview
Go deeper on 2007-007907-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007907-34.